Press Releases

MISSISSAUGA, ON, Jan 05, 2022 – Shield Therapeutics plc (LSE: STX), a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces that it has entered into an exclusive licence agreement (“the Agreement”) for Accrufer® with KYE Pharmaceuticals Inc. (“KYE”) in Canada.

Jan 05, 2022 at 08:10 AM EDT

MISSISSAUGA, ON, June 03, 2021 (CANADA NEWSWIRE) – KYE Pharmaceuticals Inc. (“KYE”) today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canada’s approval of Medunik’s New Drug Submission (NDS) for Ruzurgi®.

June 03, 2021 at 3:10 PM EDT

MISSISSAUGA, ON, May 04, 2021 (CANADA NEWSWIRE)  CORZYNA™ (ranolazine extended-release tablets) has now been made commercially available and is in wholesalers across Canada after a positive expedited review by Health Canada. 

May 04, 2021 at 8:30 AM EDT

CORZYNA™ is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies

January 5, 2021 at 9:00 AM EDT

MISSISSAUGA, ON, October 28, 2020 (CANADA NEWSWIRE) – KYE Pharmaceuticals Inc. (“KYE”), a private company headquartered in Mississauga, Ontario focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced an important milestone, FIRDAPSE® …

October 28, 2020 at 10:40 AM EDT

Notice of Application for Judicial Review Filed Today in the Federal Court of Canada. CORAL GABLES, Fla., Aug. 26, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and …

August 26, 2020 at 9:40 AM EDT

CORAL GABLES, Fla., Aug. 18, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular …

August 18, 2020 at 8:03 AM EDT

MONMOUTH JUNCTION, N.J. and MISSISSAUGA, OntarioJuly 9, 2020 /CNW/ — Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and …

July 09, 2020, 07:30 ET